CN103533995B - 提纯米卡芬净的方法 - Google Patents
提纯米卡芬净的方法 Download PDFInfo
- Publication number
- CN103533995B CN103533995B CN201280019379.XA CN201280019379A CN103533995B CN 103533995 B CN103533995 B CN 103533995B CN 201280019379 A CN201280019379 A CN 201280019379A CN 103533995 B CN103533995 B CN 103533995B
- Authority
- CN
- China
- Prior art keywords
- mfg
- salt
- water
- organic solvent
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/32—Bonded phase chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/32—Bonded phase chromatography
- B01D15/325—Reversed phase
- B01D15/327—Reversed phase with hydrophobic interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Materials For Photolithography (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161477190P | 2011-04-20 | 2011-04-20 | |
US61/477,190 | 2011-04-20 | ||
PCT/EP2012/056768 WO2012143293A1 (en) | 2011-04-20 | 2012-04-13 | Method for purification of micafungin |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103533995A CN103533995A (zh) | 2014-01-22 |
CN103533995B true CN103533995B (zh) | 2016-03-02 |
Family
ID=45953151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280019379.XA Active CN103533995B (zh) | 2011-04-20 | 2012-04-13 | 提纯米卡芬净的方法 |
Country Status (18)
Country | Link |
---|---|
US (1) | US9132163B2 (ru) |
EP (2) | EP2918324A1 (ru) |
JP (1) | JP5992507B2 (ru) |
KR (1) | KR101944512B1 (ru) |
CN (1) | CN103533995B (ru) |
AU (1) | AU2012244435B2 (ru) |
BR (1) | BR112013026420A2 (ru) |
CA (1) | CA2832145C (ru) |
DK (1) | DK2699327T3 (ru) |
ES (1) | ES2547827T3 (ru) |
HR (1) | HRP20151033T1 (ru) |
HU (1) | HUE027806T2 (ru) |
IL (1) | IL228913A (ru) |
PL (1) | PL2699327T3 (ru) |
RS (1) | RS54240B1 (ru) |
RU (1) | RU2583262C2 (ru) |
SI (1) | SI2699327T1 (ru) |
WO (1) | WO2012143293A1 (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS54240B1 (en) * | 2011-04-20 | 2015-12-31 | Xellia Pharmaceuticals Aps | PROCEDURE FOR PURIFICATION OF MIKAFUNGIN |
CN102775476B (zh) * | 2011-05-12 | 2015-01-07 | 上海天伟生物制药有限公司 | 一种米卡芬净钠盐的制备方法 |
CN105254721B (zh) * | 2014-05-13 | 2021-05-18 | 江苏豪森药业集团有限公司 | 米卡芬净的纯化转盐方法 |
US10183973B2 (en) * | 2014-05-29 | 2019-01-22 | Shanghai Techwell Biopharmaceutical Co., Ltd. | Solvate of cyclic peptide compound, preparation method for same, and uses thereof |
EP3150624A4 (en) * | 2014-05-29 | 2017-12-20 | Shanghai Techwell Biopharmaceutical Co., Ltd | Crystal of cyclic peptide compound, preparation method for same, and uses thereof |
CN105693824A (zh) * | 2015-08-27 | 2016-06-22 | 博瑞生物医药(苏州)股份有限公司 | 一种降低米卡芬净钠原料药溶剂残留量的方法 |
KR101880179B1 (ko) * | 2016-11-03 | 2018-07-20 | 한국생명공학연구원 | 미카펀진(micafungin) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 항바이러스용 약학적 조성물 |
CN108250274A (zh) * | 2016-12-28 | 2018-07-06 | 浙江华谱新创科技有限公司 | 米卡芬净高效分离纯化方法 |
EP3485873A1 (en) * | 2017-11-17 | 2019-05-22 | Cadila Healthcare Limited | Stable pharmaceutical injectable compositions of micafungin |
CN113087775B (zh) * | 2018-05-31 | 2022-07-08 | 杭州中美华东制药有限公司 | 米卡芬净钠新晶型ii及其制备方法 |
CN111909244A (zh) * | 2020-08-14 | 2020-11-10 | 卓和药业集团有限公司 | 一种高纯度米卡芬净前体fr901379的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202309A (en) * | 1989-06-30 | 1993-04-13 | Merck & Co., Inc. | Antibiotic cyclopeptide fermentation product |
CN1337968A (zh) * | 1998-12-09 | 2002-02-27 | 伊莱利利公司 | 蓝刺菌素环肽化合物的纯化 |
EP2236513A1 (en) * | 2009-03-24 | 2010-10-06 | Cadila Healthcare Limited | An improved purification process for lipopeptides |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901379A (fr) | 1943-09-10 | 1945-07-25 | Télégraphie par variations de fréquence | |
IE912046A1 (en) | 1990-06-18 | 1991-12-18 | Fujisawa Pharmaceutical Co | New polypeptide compound and a process for preparation¹thereof |
EP0788511B1 (en) | 1994-10-07 | 2002-12-11 | Fujisawa Pharmaceutical Co., Ltd. | Cyclic hexapeptides having antibiotic activity |
US6227164B1 (en) | 1998-04-24 | 2001-05-08 | Cooper Automotive Products, Inc. | Insulator shield for spark plug |
JP2005053782A (ja) * | 2001-08-31 | 2005-03-03 | Fujisawa Pharmaceut Co Ltd | 環状リポペプチド化合物の新規結晶 |
US7199248B2 (en) | 2002-08-08 | 2007-04-03 | Astellas Pharma Inc. | Process |
TW200826957A (en) * | 2006-10-16 | 2008-07-01 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Purification processes for echinocandin-type compounds |
CN106397543A (zh) * | 2010-09-28 | 2017-02-15 | 中化帝斯曼制药有限公司荷兰公司 | 用于分离环六肽的方法 |
AU2011307731B2 (en) * | 2010-09-29 | 2016-02-18 | Shanghai Techwell Biopharmaceutical Co., Ltd. | Process for purifying cyclic lipopeptide compounds or salts thereof |
RS54240B1 (en) * | 2011-04-20 | 2015-12-31 | Xellia Pharmaceuticals Aps | PROCEDURE FOR PURIFICATION OF MIKAFUNGIN |
-
2012
- 2012-04-13 RS RS20150599A patent/RS54240B1/en unknown
- 2012-04-13 RU RU2013150600/05A patent/RU2583262C2/ru not_active IP Right Cessation
- 2012-04-13 HU HUE12713998A patent/HUE027806T2/en unknown
- 2012-04-13 KR KR1020137030626A patent/KR101944512B1/ko active IP Right Grant
- 2012-04-13 EP EP15165834.1A patent/EP2918324A1/en not_active Withdrawn
- 2012-04-13 PL PL12713998T patent/PL2699327T3/pl unknown
- 2012-04-13 AU AU2012244435A patent/AU2012244435B2/en not_active Ceased
- 2012-04-13 JP JP2014505576A patent/JP5992507B2/ja not_active Expired - Fee Related
- 2012-04-13 CN CN201280019379.XA patent/CN103533995B/zh active Active
- 2012-04-13 CA CA2832145A patent/CA2832145C/en active Active
- 2012-04-13 DK DK12713998.8T patent/DK2699327T3/en active
- 2012-04-13 US US14/110,477 patent/US9132163B2/en active Active
- 2012-04-13 ES ES12713998.8T patent/ES2547827T3/es active Active
- 2012-04-13 SI SI201230299T patent/SI2699327T1/sl unknown
- 2012-04-13 WO PCT/EP2012/056768 patent/WO2012143293A1/en active Application Filing
- 2012-04-13 BR BR112013026420-9A patent/BR112013026420A2/pt not_active Application Discontinuation
- 2012-04-13 EP EP12713998.8A patent/EP2699327B1/en active Active
-
2013
- 2013-10-16 IL IL228913A patent/IL228913A/en active IP Right Grant
-
2015
- 2015-09-29 HR HRP20151033TT patent/HRP20151033T1/hr unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202309A (en) * | 1989-06-30 | 1993-04-13 | Merck & Co., Inc. | Antibiotic cyclopeptide fermentation product |
CN1337968A (zh) * | 1998-12-09 | 2002-02-27 | 伊莱利利公司 | 蓝刺菌素环肽化合物的纯化 |
EP2236513A1 (en) * | 2009-03-24 | 2010-10-06 | Cadila Healthcare Limited | An improved purification process for lipopeptides |
Also Published As
Publication number | Publication date |
---|---|
ES2547827T3 (es) | 2015-10-08 |
EP2699327B1 (en) | 2015-07-01 |
DK2699327T3 (en) | 2015-10-05 |
AU2012244435A1 (en) | 2013-10-24 |
EP2699327A1 (en) | 2014-02-26 |
SI2699327T1 (sl) | 2015-11-30 |
IL228913A0 (en) | 2013-12-31 |
ES2547827T8 (es) | 2015-10-21 |
US9132163B2 (en) | 2015-09-15 |
JP2014511886A (ja) | 2014-05-19 |
BR112013026420A2 (pt) | 2020-11-03 |
AU2012244435B2 (en) | 2017-06-15 |
RU2013150600A (ru) | 2015-05-27 |
CN103533995A (zh) | 2014-01-22 |
WO2012143293A1 (en) | 2012-10-26 |
RU2583262C2 (ru) | 2016-05-10 |
CA2832145C (en) | 2020-10-20 |
HRP20151033T1 (hr) | 2015-11-06 |
RS54240B1 (en) | 2015-12-31 |
US20140371423A1 (en) | 2014-12-18 |
EP2918324A1 (en) | 2015-09-16 |
PL2699327T3 (pl) | 2015-12-31 |
IL228913A (en) | 2017-03-30 |
HUE027806T2 (en) | 2016-11-28 |
KR101944512B1 (ko) | 2019-01-31 |
JP5992507B2 (ja) | 2016-09-14 |
CA2832145A1 (en) | 2012-10-26 |
KR20140029453A (ko) | 2014-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103533995B (zh) | 提纯米卡芬净的方法 | |
DK2464374T3 (en) | SEPARATION AND / OR CLEANING PNEUMOCANDIN B0 FROM C0 | |
CN101830970A (zh) | 一种高纯度达托霉素(Daptomycin)的纯化制备方法 | |
JP2013509365A (ja) | コリスチンの精製方法および精製コリスチン成分 | |
WO2005108977A2 (en) | Methods and systems for detection of macrolides | |
US20190194258A1 (en) | Method for controlling impurity of cyclosporin a eye gel | |
Uribe et al. | Chromatographic methods for echinocandin antifungal drugs determination in bioanalysis | |
CN106568620A (zh) | 盐酸万古霉素杂质11、13和15高纯度样品的制备方法 | |
CN102690333B (zh) | 一种高纯度替考拉宁的制备方法 | |
Enrique et al. | Application of an experimental design for the optimization and validation of a new HPLC method for the determination of vancomycin in an extemporaneous ophthalmic solution | |
SA99191248B1 (ar) | مشتقات اكينوكاندين echinocandin وطريقة تحضيرها واستخدامها كمضادات للفطريات anti-fungal | |
WO2016003135A1 (ko) | Fk506 유도체를 함유하는 크립토코쿠스 속 곰팡이 및 칸디다 속 곰팡이에 의한 진균 감염을 치료하기 위한 약제학적 조성물 및 그의 용도 | |
Nicolau et al. | Pharmacodynamics of a novel des-F (6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model | |
SI21924A (sl) | Cist vankomicin hidroklorid | |
CN105531283A (zh) | 卡泊芬净衍生物 | |
Vicente et al. | Fungal secondary metabolites as source of antifungal compounds | |
Huang et al. | Measurement of unbound ranitidine in blood and bile of anesthetized rats using microdialysis coupled to liquid chromatography and its pharmacokinetic application | |
CN103861083A (zh) | 一种更稳定的棘白菌素类抗真菌剂的药用组合物 | |
Itoh et al. | Stereoselective renal secretion of carbenicillin in rabbits: role of the organic anion transporter at the renal brush border membrane | |
Lewis et al. | Antifungal agents | |
AU2020237983A1 (en) | Stable pharmaceutical formulations of peptide and protein drugs | |
CN115993422A (zh) | 聚山梨醇酯类的测定 | |
Chen et al. | High-performance liquid chromatographic determination of cilastatin and its major metabolite N-acetylcilastatin in rat plasma, urine and bile | |
Sawada et al. | P-Glycoprotein-Mediated Transport of | |
CN101333249A (zh) | 棘白菌素衍生物、其制备方法及其作为抗真菌剂的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |